Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06513962 · ClinicalTrials.gov registry record · Phase 3
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
A Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06513962: Recruiting Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Children's Oncology Group.
NCT06513962 is a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 60 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06513962, a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Primary Outcome
Number of enrollments by the end of the DOD funded grant period, and ideally prior to Year 4 to enable greater duration of follow-up time.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
- OTHER Best Practice
- OTHER Electronic Health Record Review
- DRUG Triptorelin Pamoate
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- Loma Linda University Medical Center - Loma Linda
- Mattel Children's Hospital UCLA - Los Angeles
- Kaiser Permanente-Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Sutter Medical Center Sacramento - Sacramento
- UC San Diego Medical Center - Hillcrest - San Diego
- Rady Children's Hospital - San Diego - San Diego
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- Arkansas Children's Hospital - Little Rock
- CARTI Cancer Center - Little Rock
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center - Denver
Delaware
- Beebe Medical Center - Lewes
- Beebe South Coastal Health Campus - Millville
Arizona
- Phoenix Childrens Hospital - Phoenix
Connecticut
- Connecticut Children's Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2029-10-30 |
| Phase | Phase 3 |
What NCT06513962 shows while recruiting
NCT06513962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06513962 names 20 study sites across 7 states, led by California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT06513962 about?
NCT06513962 is a clinical study titled "Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer". This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries....
What is the current status of trial NCT06513962?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-02-27. Estimated completion is 2029-10-30.
What conditions does trial NCT06513962 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.
What interventions are being tested in trial NCT06513962?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Best Practice (OTHER), Electronic Health Record Review (OTHER), Triptorelin Pamoate (DRUG).
Who is sponsoring clinical trial NCT06513962?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06513962 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06513962's enrollment target sits among peer trials
60 115th of 176 higher than 56 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · Phase 3
-
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RECRUITING · Phase 3
-
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
RECRUITING · Phase 3
-
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI